Organogenesis Holdings Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Organogenesis Holdings Inc.
- Former names
- Avista Healthcare Public Acquisition Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Canton
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ORGO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001661181
Board of directors
-
Alan A. Ades · DirectorSince 2023
-
Arthur S. Leibowitz · DirectorSince 2023
-
Garrett Lustig · DirectorSince 2024
-
Gary S. Gillheeney · Director · President and CEOSince 2023
-
Gilberto Quintero · DirectorSince 2023
-
Glenn H. Nussdorf · DirectorSince 2023
-
Jon L. Giacomin · DirectorSince 2023
-
Michael Joseph Driscoll · DirectorSince 2023
-
Michele Ilene Korfin · DirectorSince 2023
-
Prathyusha Duraibabu · DirectorSince 2023
Chief executives
Gary S. Gillheeney
· President and CEO
Dates unknown
Director election results
Annual meeting of June 15, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
71.6%
-
76.0%
-
89.8%
-
89.8%
-
89.9%
-
89.9%
-
90.0%
-
90.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $40,100
- 2 purchases by 2 insiders
- Sold, last 12 months
- $2,620,120
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 | Arthur S. Leibowitz Director | Open-market purchase | +5,000 | $2.68 | $13,400 |
| Mar 9, 2026 | Michael Joseph Driscoll Director | Open-market purchase | +10,000 | $2.67 | $26,700 |
| Mar 1, 2026 | Cavorsi Robert Officer (Vice President, Strategy) | Shares withheld for tax | −700 | $3.21 | $2,247 |
| Feb 18, 2026 | Freedman Lori Officer (Chief Admin. and Legal Officer) | Grant or award | +203,125 | — | — |
| Feb 18, 2026 | Cavorsi Robert Officer (Vice President, Strategy) | Grant or award | +93,750 | — | — |
| Feb 18, 2026 | Francisco David Officer (Chief Financial Officer) | Grant or award | +195,312 | — | — |
| Feb 18, 2026 | Grow Brian Officer (Chief Commercial Officer) | Grant or award | +234,375 | — | — |
| Feb 18, 2026 | Bilbo Patrick Officer (Chief Operating Officer) | Grant or award | +210,937 | — | — |
| Feb 18, 2026 | Gary S. Gillheeney Director, Officer (President and CEO) | Grant or award | +890,625 | — | — |
| Feb 18, 2026 | Michael Joseph Driscoll Director | Grant or award | +48,828 | — | — |
| Feb 18, 2026 | Jon L. Giacomin Director | Grant or award | +48,828 | — | — |
| Feb 18, 2026 | Arthur S. Leibowitz Director | Grant or award | +48,828 | — | — |
| Feb 18, 2026 | Montecalvo Antonio S. Officer (Vice President, Health Policy) | Grant or award | +40,625 | — | — |
| Feb 18, 2026 | Gilberto Quintero Director | Grant or award | +48,828 | — | — |
| Feb 18, 2026 | Prathyusha Duraibabu Director | Grant or award | +48,828 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.